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Original Article of Interventional Pulmonology Corner
Airway stent complications: the role of follow-up bronchoscopy as 
a surveillance method
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Background: Airway stenting has become an integral part of the therapeutic endoscopic management 
of obstructive benign and malignant central airway diseases. Despite increased use of airway stents and 
frequent stent-associated complications, no clear guidelines for surveillance and maintenance exist. This 
study aim is to elucidate predictive factors associated with development of stent complications, as well as an 
optimal surveillance period for follow-up bronchoscopy for early detection and possible prevention of stent-
associated complications. 
Methods: Retrospective cohort study of all patients who underwent airway stent placements at our 
institution from April 2010 to December 2013 for benign and malignant airway diseases. Metallic, silicone 
(straight, Y stent, T-tube) and hybrid stents were included in the study. Stent complications were analyzed 
at the time of follow-up bronchoscopy performed four to six weeks after initial stent placement or earlier if 
patients became symptomatic. 
Results: The study included 134 patients of which 147 stents were placed. Follow-up bronchoscopy was 
performed in 94 patients. Symptomatic status at the time of follow-up bronchoscopy was not associated 
with stent complications [odds ratio (OR) =1.88; 95% CI: 0.79–4.45; P=0.15]. Patient age, sex, indication 
for stent placement, and stent location, were not associated with development of complications (all P>0.05). 
Compared to all other stents, hybrid stents were more likely to migrate (OR =6.60; 95% CI: 2.16–20.2; 
P=0.001) or obstruct by secretions (OR =2.53; 95% CI: 1.10–5.84; P=0.03). There were no complications 
associated with surveillance bronchoscopy.
Conclusions: Surveillance bronchoscopy within 4 to 6 weeks of stent placement may be useful for 
early detection of complications and their subsequent management, regardless of symptomatic status and 
indication for stent placement. Prospective multicenter studies are needed to compare optimal surveillance 
methods and the impact on patient mortality, morbidity and healthcare costs. 
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Introduction
Over the past two decades, airway stenting has become an 
integral part of the therapeutic endoscopic management of 
obstructive benign and malignant central airway diseases. 
Airway stent insertions often achieve immediate relief of 
dyspnea (1-6). Moreover, airway stenting has consistently 
improved airflow obstruction parameters on pulmonary 
function testing (3,7-10). Significant improvement in 
the Eastern Cooperative Oncology Group (ECOG) 
performance score has also been reported in patients with 
malignant disease after stent placement (2,11).
Along with well-established palliative and therapeutic 
benefits, stent-related complications have also been 
reported with use of  metal l ic  and si l icone stents 
(2,5,12-17). These include stent migrations, stent fractures, 
stent-associated infections, and stent obstructions by tumor, 
granulation tissue and secretions. Follow-up endoscopic 
interventions are often needed to maintain airway patency 
and prevent further complications (6,12,17). Despite 
increased use of airway stents and frequent stent-associated 
complications, most interventional pulmonologists do not 
have defined follow-up or maintenance protocols to adhere 
to (18).
This study represents our institutional experience 
of various airway stent placements and follow-up 
bronchoscopies for management of obstructive benign and 
malignant central airway diseases. The study hypothesis 
is that follow-up bronchoscopy 4-6 weeks after stent 
placement allows for early detection of stent-related 
complications regardless of symptomatic status, which may 
serve as an optimal surveillance point to prevent further 
respiratory complications. 
Methods
Study design
We performed a retrospective cohort study of all patients 
who underwent placement of at least one airway stent at 
the Johns Hopkins Hospital from April 2010 to December 
2013. Patients were identified using the following 
current procedural terminology (CPT) codes: 31631 
[bronchoscopy, rigid or flexible, including fluoroscopic 
guidance, when performed; with placement of tracheal 
stent(s)], 31636 [bronchoscopy, rigid or flexible, including 
fluoroscopic guidance, when performed; with placement 
of bronchial stent(s), initial bronchus], and 31637 
[bronchoscopy, rigid or flexible, including fluoroscopic 
guidance, when performed; each additional major 
bronchus stented].
The study was approved by the Johns Hopkins 
institutional review board (00028714) with waiver to 
informed consent provided. Patient data was retrieved 
from electronic medical records using a standardized form. 
All definitions were developed prior to chart abstraction 
to ensure consistency. Demographic (age, gender), stent 
data (stent type, location, and indication) and surveillance 
bronchoscopy findings were collected.
Follow-up bronchoscopy was performed according to 
the clinical protocol of our department for airway stenting, 
between 4–6 weeks following stent insertion or if patients 
became symptomatic, whichever occurred earlier. For 
patients who underwent a follow-up bronchoscopy any 
time after the initial stent insertion, we abstracted data on 
the type of bronchoscope used, symptomatic status prior 
to the bronchoscopy, stent-related complications, and 
therapeutic interventions performed during bronchoscopy. 
The primary outcome was development of stent-related 
complications, defined as stent migrations/fractures or 
obstruction by tumor, granulation tissue or secretions 
detected on follow-up bronchoscopy. 
Statistical analysis
Patient and stent characteristics are presented overall, 
and by follow-up bronchoscopy status as means (standard 
deviations) for continuous variables and as percentages 
for categorical variables. Characteristics by follow-up 
bronchoscopy status were compared using Student’s 
t-tests and chi square tests. Clustering of stents within 
patients who had more than one stent placed during initial 
bronchoscopy was accounted for using the generalized 
estimating equations (GEE) model with independent 
correlation structure. Odds ratios (ORs) (with 95% CIs) 
for the presence of complications among those who 
underwent follow-up bronchoscopy were obtained from 
the GEE models. Univariate and multivariate analyses 
were performed. Variables included in the models were: 
age, sex, indication for stent placement, stent location, 
stent type and symptoms at the time of follow-up 
bronchoscopy. All reported P values are two-sided and 
P<0.05 was considered statistically significant. All analyses 
were performed using Stata Version 13 (StataCorp, 
College Station, Texas, USA).
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Results
Patient characteristics
There were 134 patients with central airway obstruction 
with a total of 147 airway stents placed. Ten patients had 
more than one stent placed during the initial bronchoscopy. 
Seventy seven patients (58%) were women (Table 1). Mean 
patient age was 55.9±15.5 years. Eighty six patients (64%) 
underwent stent placement for malignant airway disease, 
half of whom had non-small cell lung cancer, while other 
malignant indications included small cell lung cancer, 
esophageal cancer, lymphoma, and lung metastases from 
variety of primary malignancies (6 sarcoma, 3 breast, 
2 renal, 2 thyroid, 1 head and neck, 1 hepatoblastoma and 
1 unknown primary). 
Leading benign indications for airway stenting (48 
patients) were idiopathic or post-intubation tracheal stenosis 
(23 patients), as well as post lung transplantation bronchial 
stenosis, tracheobronchomalacia, pulmonary aspergillosis, 
papillomatosis and tracheoesophageal fistula.
Among the 134 patients, who had an airway stent placed 
during the initial bronchoscopy, 94 (70%) had follow-
up bronchoscopy of which 61% were women, 54% had a 
malignant indication for stent placement, and 63% were 
symptomatic at the time of the bronchoscopy (Table 1). 
These 94 patients had a total of 100 stents (5 patients had 
more than one stent). The mean time from stent placement 
to follow-up bronchoscopy was 41.2 days. There were no 
complications associated with follow-up bronchoscopy. 
Stent characteristics
The types and locations of the stents inserted during the 
initial bronchoscopy are outlined in Table 2. The most 
common stent was the hybrid stent (42.9%), followed 
by the straight silicone stent (22.4%), and the Y-stent 
(20.4%). The metallic stent accounted for only 7.5% 
of the stents, as it was taken off the market in 2011. All 
metallic stent placements were performed for malignant 
airway obstruction only. Of note, all patients with a T-tube 
had a follow-up bronchoscopy. Tracheal stents placed for 
indications of tracheal stenosis and tracheomalacia were 
well represented in the group of patients who underwent 
follow-up bronchoscopy.
More than two thirds of all stents placed were associated 
with at least one complication at the time of the follow-up 
bronchoscopy, such as migration, fracture, and obstruction 
by tumor, granulation tissue and secretions (Table 2). 
Nineteen stents were found to have complications within 
5 days of placement, requiring therapeutic intervention 
during the follow-up bronchoscopy.
Analysis of stent complications
In univariate analysis of patients, who underwent follow-up 
bronchoscopy, the presence of dyspnea and having hybrid 
stents were independent predictive factors of stent-related 
complications (Table 3). Stent-related complications did not 
necessarily correlate with respiratory symptoms [odds ratio 
(OR) 1.88, 95% CI: 0.79–4.45], as 60% of asymptomatic 
patients were found to have at least one stent-related 
complication on follow-up bronchoscopy. Moreover, patient 
age, sex, and stent indication/location, were not predictive 
of development of stent-related complications. 
In multivariate analysis, the presence of dyspnea was 
no longer an independent predictive factor of stent-
related complications discovered during the follow-up 
bronchoscopy (OR 2.36, 95% CI: 0.72–7.70). The hybrid 
stents continued to have increased risk of stent-related 
complications compared to the metallic, Y, and T-tube 
stents (metallic: OR 0.02, 95% CI: 0.002–0.29; Y-stent: OR 
0.10, 95% CI: 0.01–0.78; T-tube: OR 0.06, 95% CI: 0.01–
0.60). Of note, the straight silicone stent was associated 
with lower odds of complications compared to the hybrid 
stent, although this association did not reach statistical 
significance (OR 0.17, 95% CI: 0.03–1.00).
Given the higher incidence of stent-related complications 
with hybrid stents, we performed further analysis to 
determine the likelihood of individual stent-related 
complications associated with hybrid stents, compared to all 
other stents used in our study. Stent migration (OR =6.60, 
95% CI: 2.16–20.2) and stent obstruction by secretions (OR 
=2.53, 95% CI: 1.10–5.84) were significantly more likely to 
occur with hybrid stents (Table 4).
Discussion
Approximately 30% of patients with lung cancer develop 
central airway obstruction and may require airway stents as 
part of their management (19). Though surgical resection 
remains the gold standard for management of benign 
airway stenosis, airway stents can serve as a trial to assess for 
symptomatic improvement prior to surgery and also can be 
therapeutically utilized in patients with inoperable strictures 
or deemed poor surgical candidates due to underlying 
comorbidities (20).
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Table 1 Patient characteristics overall and stratified by follow-up bronchoscopy status
Characteristic All patients (N=134)
Patients with follow-up 
bronchoscopy (n=94)
Patients without follow-up 
bronchoscopy (n=40)
P value*
Age (years), mean (SD) 55.9 (15.5) 56.1 (13.8) 55.4 (19.1) 0.812
Female, n (%) 77 (57.5) 57 (60.6) 20 (50.0) 0.254
Type of airway obstruction, n (%)
Malignant 86 (64.2) 51 (54.3) 35 (87.5) <0.001
Malignant airway obstruction causes, n
Non-small cell lung cancer 43 20 23
Small cell lung cancer 11 8 3
Esophageal cancer 9 7 2
Lymphoma 5 3 2
Metastases to lung 18 13 5
Benign airway obstruction causes, n
Tracheal stenosis 23 21 2
Tracheal/bronchial malacia 10 10 0
Airway stenosis after lung transplant 10 10 0
Pulmonary aspergillosis 3 1 2
Other 2 1 1
Type of f/u bronchoscopy, n (%)
Flexible – 47 (50.0) –
Rigid – 6 (6.4) –
Both flexible and rigid – 41 (43.6) –
Symptoms at time of f/u bronchoscopy
Asymptomatic, n (%) – 35 (37.2) –
Symptomatic, n (%)** – 59 (62.8) –
Dyspnea, n – 37 –
Cough, n – 14 –
Respiratory failure, n – 10 –
Excess secretions, n – 4 –
Dysphagia, n – 3 –
*, P value comparing characteristics of patients with and without follow-up bronchoscopy; **, some patients had more than one symptom 
at the time of bronchoscopy.
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Table 2 Stent characteristics overall and stratified by follow-up bronchoscopy status
Characteristic All stents (N=147)
Stents in patients with follow-
up bronchoscopy (n=100)
Stents in patients without follow-up 
bronchoscopy (n=47)
P value*
Stent type, n (%)
Hybrid (Merit Endotek) 63 (42.9) 40 (40.0) 23 (48.9) 0.31
Metallic (Boston Scientific) 11 (7.5) 6 (6.0) 5 (10.6) 0.32
Straight silicone stent (Novatech) 33 (22.4) 23 (23.0) 10 (21.3) 0.82
Y stent (Novatech) 30 (20.4) 21 (21.0) 9 (19.2) 0.80
T-tube (Boston Medical Products) 10 (6.8) 10 (10.0) 0 (0.0) 0.025
Stent location, n (%)
Trachea 44 (29.9) 37 (37.0) 7 (14.9) 0.006
Carina (Y stent) 30 (20.4) 21 (21.0) 9 (19.1) 0.80
Left mainstem bronchus 20 (13.6) 11 (11.0) 9 (19.1) 0.18
Right mainstem bronchus 10 (6.8) 7 (7.0) 3 (6.4) 0.89
Bronchus intermedius 39 (26.5) 24 (24.0) 15 (31.9) 0.31
Other** 4 (2.7) 0 (0.0) 4 (8.5) 0.003
Stent-related complications
No complications, n (%) – 31 (31.0) –
Complication found, n (%)*** – 69 (69.0) –
Obstruction by secretions, n – 37 –
Obstruction by tumor/granulation 
tissue, n
– 27 –
Migration, n – 20 –
Fracture, n – 1 –
Distortion, n – 1 –
Therapeutic interventions
No intervention, n (%) – 26 (26.0) –
Intervention performed, n (%)**** – 74 (74.0) –
Aspiration of secretions, n – 36 –
Stent removal, n – 27 –
Stent replacement, n – 13 –
Tumor/GT resection, n – 12 –
Balloon dilation, n – 12 –
Stent repositioning, n – 4 –
Additional stent insertion, n – 4 –
*, P value comparing characteristics of stents among patients who did and did not undergo follow-up bronchoscopy. Each stent type and 
location is compared to all other stent types and locations, respectively; **, other stent locations included the left lower lobe (n=3) and the 
left upper lobe (n=1); ***, some stents were affected by more than one complication; ****, more than one intervention was performed on 
some stents. GT, granulation tissue. 
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Table 3 Univariate analysis for the presence of any stent-related complication among patients who underwent follow-up bronchoscopy
Characteristic Odds ratio 95% CI P value
Age (>55 vs. ≤55 years) 1.18 0.49–2.84 0.71
Sex (female vs. male) 1.36 0.58–3.21 0.48
Indication for stent placement (malignant vs. benign) 0.93 0.40–2.19 0.88
Stent location
Trachea 1.00 Reference –
Carina (Y-stent) 0.72 0.24–2.16 0.56
Left mainstem bronchus 0.95 0.23–3.85 0.94
Right mainstem bronchus 3.25 0.35–30.0 0.30
Bronchus intermedius 2.71 0.76–9.63 0.12
Stent type 
Hybrid 1.00 Reference –
Metallic 0.09 0.01–0.59 0.01
Straight silicone stent 0.40 0.12–1.40 0.15
Y stent 0.24 0.07–0.80 0.02
T-tube 0.18 0.04–0.80 0.03
Symptoms*
Any symptom (yes vs. no) 1.88 0.79–4.45 0.15
Dyspnea (yes vs. no) 2.80 1.06–7.35 0.04
Cough (yes vs. no) 1.77 0.46–6.86 0.41
Respiratory failure (yes vs. no) 0.40 0.12–1.35 0.14
*, excess secretions and dysphagia were not analyzed individually as symptoms because their incidence was too small.
Table 4 Univariate analysis for the presence of individual stent-related complications in hybrid compared to non-hybrid stents
Hybrid stents vs. non-hybrid stents Odds ratio 95% CI P value
Obstruction by tumor/granulation tissue 0.84 0.34–2.09 0.71
Obstruction by secretions 2.53 1.10–5.84 0.03
Stent migration 6.60 2.16–20.2 0.001
For both malignant and benign airway diseases, airway 
stents provide significant symptomatic benefit, decrease 
airflow obstruction, and improve quality of life (1-11). 
Despite many benefits, airway stents are foreign bodies 
prone to complications (21). Even with frequent stent-
associated complications, guidelines for surveillance and 
maintenance of these stent remain inadequate18. This study 
confirms that stent-related complications are common, and 
highlights the potential role of follow-up bronchoscopy as a 
stent surveillance method.
The reported stent-related complication rate has varied 
in the literature (mostly 40–60%, and as high as 87% at 
20 months), based on the study population and the types/
material of airway stents deployed (2,13-17,22). The 
complication rate in our study (69%) falls within this range.
Stent complications have often been shown to occur 
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within the first 2 to 3 months following stent placement 
and some, such as stent migration and granulation tissue 
formation, may manifest as early as 3 days later (4,12,23,24). 
In fact, nineteen stents (19.0%) in our study were found to 
have complications within 5 days of insertion. 
In addition, loss of airway stent patency is most rapid 
during the first year following stent placement, often 
requiring bronchoscopic interventions (6,12,15). For 
metallic stents, neoepithelialization with incorporation 
of the stent within the airway wall can occur as early as 
3–6 weeks; complications during removal of these stents 
were more likely to occur the longer they had been in 
place (25,26).
In benign airway stenosis, temporary airway stents can 
potentially provide long-term airway patency even after the 
stent removal. Appropriate surveillance and maintenance 
of these stents is essential, as longer these stents are kept, 
the higher the likelihood of long-term airway patency 
after stent removal (27). These findings from our and 
other studies suggest that stent-related complications are 
common, and can occur early, and often require early 
therapeutic intervention to maintain airway patency.
While  presence of  symptoms in pat ients  a f ter 
stent placement is a clear indication for a follow-
up bronchoscopy, the method of stent surveillance in 
asymptomatic patients is less clear and unestablished. 
In one study, routine surveillance bronchoscopy of 
asymptomatic patients within 2 to 3 months after stent 
insertion did not result in detection of high incidence of 
stent-related complications (28). In our study, however, 
absence of symptoms did not always correlate with stent-
associated complications. The two studies are similar in size 
and patient population, but our study examined multiple 
stent types (metallic, silicone, and hybrid), rather than 
silicone stents alone, which may explain the difference 
in findings. Our study suggests that routine surveillance 
bronchoscopy, regardless of symptomatic status, may play a 
role in early detection of stent-related complications, with 
a goal to delay likely future sequelae of post-obstructive 
pneumonia and respiratory failure. The impact of routine 
surveillance bronchoscopy on patient mortality, morbidity, 
hospitalization, and overall health costs remains to be 
determined. 
A survey by Hoag e t  a l .  revealed that  61% of 
interventional pulmonologists discovered stent-related 
complications via various surveillance methods, including 
physical examination, chest radiography, computed 
tomography (CT), bronchoscopy and fluoroscopy (18). 
There is limited data to compare the efficacy of these 
different surveillance methods at detecting stent-related 
complications. Small studies showed that CT was an 
accurate, non-invasive method to evaluate airway stents 
and airway patency, though unable to characterize stent 
epithelialization and subtle stenoses (29,30).
To our knowledge, our study includes the largest 
number of hybrid stents ever studied. The hybrid stent 
is a self-expanding stent, which combines the features of 
metallic and silicone stents, with a hydrophilic coating 
and completely covered nitinol framework. Our study 
shows that hybrid stents are associated with higher rates 
of migration and significant obstruction by secretions, 
compared to other stents. Smaller studies have also reported 
the occurrence of these complications. In one study, which 
evaluated recurrent bronchus intermedius strictures in 
lung transplant recipients, mucus buildup was detected in 
all 6 stents, and immediate migration was seen in 5 out of 
6 stents (31). In another study, four out of five hybrid stents 
were affected by migration in benign airway stenoses (13).
The strengths of our study include the relatively large 
patient sample, the diversity of indications for stent 
placement, and the variety of stents used. The main 
limitation of our study was its retrospective nature; as such, 
multicenter, prospective studies are needed to validate the 
optimal period of surveillance bronchoscopy for long-
term benefits. Another limitation of our study was that 
about a third of our patients did not undergo follow-up 
bronchoscopy due to primarily to death or transition to 
hospice care. Furthermore, we did not evaluate for stent-
associated respiratory tract infection, which is known to 
occur in 15 to 20% of patients with stents (16,32,33). 
Finally, it remains to be determined, whether the early 
bronchoscopic detection of stent-related complications in 
asymptomatic patients can prevent subsequent symptom 
development or clinical deterioration. Prospective trials 
are needed to adequately define the role of surveillance 
bronchoscopy.
Conclusions
Surveillance bronchoscopy within 4 to 6 weeks of 
stent placement may be useful for early detection of 
complications and their subsequent management, 
regardless of symptomatic status and indication for stent 
placement. Prospective multicenter studies are needed 
to compare optimal surveillance methods and determine 
how surveillance bronchoscopy affects patient mortality, 
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morbidity and healthcare costs. 
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